ReviewCurrent nutrition reports2025
Recent Nutraceutical Interventions for Hypertension: A Comprehensive Review of Randomized Clinical Evidence.
Review in Current nutrition reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHypertension remains a critical global health issue, affecting nearly half of the adult population worldwide. The limitations of conventional pharmacological treatments such as adverse side effects, challenges in adherence, and increasing healthcare costs underscore the need for alternative and complementary approaches. This review aims to discuss recent non-pharmacological strategies, particularly nutraceuticals, as potential solutions for hypertension management. RECENT
findingsNutraceuticals, including omega-3 fatty acids, coenzyme Q10, garlic extract, and magnesium, demonstrate promise in regulating blood pressure through mechanisms like endothelial function improvement, oxidative stress reduction, and inflammation control. Evidence from randomized clinical trials (2020– May 2025) highlights modest yet significant reductions in systolic and diastolic blood pressure with nutraceutical use, suggesting their complementary role alongside traditional antihypertensive regimens. Functional foods, rich in potassium and magnesium, further support blood pressure control through vascular relaxation and enhanced muscle and nerve function. These interventions offer several advantages, including fewer side effects, improved patient compliance, and cost-effectiveness. While nutraceuticals provide a promising alternative, challenges persist regarding optimal dosing, long-term safety, and efficacy across diverse populations. Future research must focus on addressing these gaps and establishing robust clinical guidelines to integrate nutraceuticals into mainstream hypertension management practices. When combined with other lifestyle interventions, nutraceuticals could present a holistic approach to reducing cardiovascular risks, enhancing the quality of life for hypertensive patients globally.
Indexed as
Identifiers
40593444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.